USPTO Rejects HIV/AIDS Drug Patents after considering prior art

On 23 January, 2008 the Public Patent Foundation announced that the USPTO rejected four patents assigned to Gilead Sciences that related to the HIV/AIDS drug tenofovir disoproxil fumarate (TDF). The Public Patent Foundation filed a third party request for re-examination, submitting prior art that had not been disclosed in the patent prosecution process. For more information on the patents, the reexaminations, and the Public Patent Foundation, see: http://www.pubpat.org/gileadhivaidsdrug.htm.